Patient-reported outcome-informed individualized dose and schedule modification of enfortumab vedotin plus pembrolizumab in a nonagenarian patient with metastatic bladder cancer: a case report.
Treatment opportunities using the enfortumab vedotin plus pembrolizumab (EV+P) combination are expanding for patients with unresectable or metastatic urothelial carcinoma. We report the case of a 93-year-old man with bladder cancer and lung metastases who received EV+P therapy and achieved a complete response. By omitt...